Cresco Labs (CRLBF) Depreciation & Amortization (CF) (2019 - 2026)
Cresco Labs (CRLBF) posted Depreciation & Amortization (CF) of $12.2 million for Q1 2026, up 13.53% on a QoQ basis from $10.8 million in Q4 2025, and down 5.35% year-over-year from $12.9 million in Q1 2025.
Cresco Labs (CRLBF) Depreciation & Amortization (CF) (2019 - 2026) Analysis & Trends
Cresco Labs' Depreciation & Amortization (CF) history runs 8 years deep, the most recent figure standing at $12.2 million for Q1 2026.
- Quarterly Depreciation & Amortization (CF) fell 5.35% year-over-year to $12.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $48.0 million (down 15.27% YoY) and the FY2025 annual result came in at $48.7 million, down 17.57% from the prior year.
- Depreciation & Amortization (CF) was $12.2 million for Q1 2026 at Cresco Labs, up from $10.8 million in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $20.3 million in Q4 2023 and bottomed at $10.8 million in Q4 2025.
- A 5-year average of $13.8 million and a median of $13.4 million in 2022 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) surged 40.04% — and 2024, when it tumbled 31.35%.
- Cresco Labs' Depreciation & Amortization (CF) stood at $14.5 million in 2022, then jumped by 40.04% to $20.3 million in 2023, then tumbled by 31.35% to $13.9 million in 2024, then fell by 22.62% to $10.8 million in 2025, then gained by 13.53% to $12.2 million in 2026.
- Business Quant data shows CRLBF's Depreciation & Amortization (CF) at $12.2 million in Q1 2026, $10.8 million in Q4 2025, and $12.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 239.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.04 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 22.60 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 676.10 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 7.20 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 172.00 Mn |
| 10 | Cresco Labs | 254.96 Mn | 99.57 Mn | 75.45 Mn | 12.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.22 Mn |
| Mar 31, 2026 | 12.22 Mn |
| Dec 31, 2025 | 10.76 Mn |
| Dec 31, 2025 | 10.76 Mn |
| Sep 30, 2025 | 12.86 Mn |
| Sep 30, 2025 | 12.86 Mn |
| Jun 30, 2025 | 12.19 Mn |
| Jun 30, 2025 | 12.19 Mn |
| Mar 31, 2025 | 12.91 Mn |
| Mar 31, 2025 | 12.91 Mn |
| Dec 31, 2024 | 13.90 Mn |
| Dec 31, 2024 | 13.90 Mn |
| Sep 30, 2024 | 14.93 Mn |
| Sep 30, 2024 | 14.93 Mn |
| Jun 30, 2024 | 14.93 Mn |
| Jun 30, 2024 | 14.93 Mn |
| Mar 31, 2024 | 15.33 Mn |
| Mar 31, 2024 | 15.33 Mn |
| Dec 31, 2023 | 20.25 Mn |
| Dec 31, 2023 | 20.25 Mn |